Hepatitis B
Traditional Chinese Medicine May Perform Better than Interferon or Lamivudine for Chronic Hepatitis B
- Details
- Category: HBV Treatment
- Published on Tuesday, 06 April 2010 13:49
- Written by Liz Highleyman
Various traditional Chinese medicine (TCM) formulations were found to work as well as or better than the pharmaceutical drugs interferon and lamivudine for people with chronic hepatitis B, according to a joint U.S./Chinese review of clinical trials published in the February 2010 issue of Hepatology. While many of these studies were considered to be of poor quality according to Western drug testing standards, the review authors concluded that some TCM remedies appear effective and warrant further study.
Entecavir (Baraclude) Works Well in Patients with Adefovir-resistant Hepatitis B, but Lamivudine Resistance Compromises Efficacy
- Details
- Category: HBV Treatment
- Published on Friday, 02 April 2010 17:12
- Written by Liz Highleyman
The nucleoside analog entecavir (Baraclude) worked well in previously untreated chronic hepatitis B patients and in people who had developed resistance to the nucleotide analog adefovir (Hepsera), but did not perform well in people with resistance to lamivudine (Epivir-HBV) according to a European study described in the April 2010 Journal of Hepatology. Among patients who developed resistance to entecavir, tenofovir (Viread) remained an effective option.
AASLD Issues Updated Practice Guidelines for Management of Chronic Hepatitis B
- Details
- Category: HBV Treatment Guidelines
- Published on Tuesday, 22 September 2009 13:49
- Written by HIVandHepatitis.com
The American Association for the Study of Liver Diseases (AASLD) published a revised version of its "Practice Guidelines for Management of Chronic Hepatitis B" in the September 2009 issue of Hepatology. Key changes are new recommendations for first-line and second-line antiviral therapy, reflecting the latest research on hepatitis B virus (HBV) treatment and the recent approval of tenofovir (Viread) for this indication.
Appetite-regulating Hormone Ghrelin May Inhibit Inflammation and Liver Fibrosis
- Details
- Category: Fibrosis & Cirrhosis
- Published on Tuesday, 23 March 2010 14:02
- Written by Liz Highleyman
Ghrelin, an appetite-regulating hormone produced primarily in the stomach, reduced liver fibrosis, inflammation, and oxidative stress in rats and protected them from both chronic and acute liver injury, according to a study published in the March 2010 issue of Hepatology. Researchers also found that ghrelin levels were lower in chronic hepatitis patients with advanced fibrosis. If confirmed in future studies, ghrelin may have potential as an anti-fibrotic therapy.
Bone Loss and Vitamin D Deficiency Are Common among People with Liver Cirrhosis
- Details
- Category: Fibrosis & Cirrhosis
- Published on Tuesday, 01 September 2009 14:01
- Written by Liz Highleyman
People with liver cirrhosis -- a potential outcome of chronic hepatitis B or C -- frequently experience bone loss, or reduced bone mineral density (BMD), and often have low vitamin D levels, according to an Indian study published in the July 28, 2009 issue of World Journal of Gastroenterology.
Boys with Chronic Hepatitis B May Experience HBeAg Seroconversion and Reduced HBV Viral Load at Puberty
- Details
- Category: HBV Basic Science
- Published on Friday, 12 March 2010 12:57
- Written by Liz Highleyman
Boys with chronic hepatitis B virus (HBV) infection may experience hepatitis B "e" antigen (HBeAg) seroconversion and see a reduction in HBV DNA levels when they reach puberty, according to a study published in the March 2010 issue of Gastroenterology. These findings shed further light on sex differences in the natural history of hepatitis B.
Should Entecavir (Baraclude) and Tenofovir (Viread) Be First-line Treatment for Chronic Hepatitis B?
- Details
- Category: HBV Treatment
- Published on Friday, 05 June 2009 13:41
- Written by DDW Daily News
At the annual Digestive Disease Week (DDW 2009) meeting this week in Chicago, a panel of experts discussed the prevention and management of antiviral drug resistance in patients receiving long-term treatment for chronic hepatitis B virus (HBV) infection, according to DDW Daily News, the official conference newspaper.
Long-term Data Show Telbivudine (Tyzeka) Suppresses HBV Viral Load and Leads to HBeAg Clearance in Chronic Hepatitis B Patients
- Details
- Category: HBV Treatment
- Published on Friday, 20 November 2009 00:00
- Written by Liz Highleyman
At the 60th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2009) this month in Boston, researchers reported 4-year data from the GLOBE study, indicating that the nucleoside analog telbivudine (Tyzeka) continues to provide long-term viral load suppression, ALT normalization, and hepatitis B "e" antigen (HBeAg) seroconversion in chronic hepatitis B patients. Another study showed sustained response up to 2 years after completing telbivudine treatment.
EASL 2009: Does HBV Viral Load Level Predict Development of Liver Fibrosis?
- Details
- Category: HBV Disease Progression
- Published on Friday, 29 May 2009 13:47
- Written by Liz Highleyman
Two studies presented at the 44th Annual Meeting of the European Association for the Study of the Liver (EASL 2009) last month in Copenhagen looked at the association between HBV DNA level and development of fibrosis, with findings suggesting that the role of HBV viral load differs for hepatitis B "e" antigen (HBeAg) negative and HBeAg positive individuals.
More Articles...
- Investigational 2-Dose Dynavax Heplisav Hepatitis B Vaccine May Work Better than Standard 3-Dose Energix-B Vaccine
- Addition of Emtricitabine (Emtriva) Does Not Improve Response to Tenofovir (Viread) for Chronic Hepatitis B
- Some Individuals Harbor HBV with Adefovir and Tenofovir Resistance Mutations before They Ever Receive Treatment
- GLOBE Trial 2-Year Data Shows Telbivudine (Tyzeka) Is More Effective than Lamivudine (Epivir-HBV) for Chronic Hepatitis B
- Adefovir (Hepsera) Prevents Post-transplant HBV Recurrence as well as HBIG
Web Design and Development by